Are Vaccinemakers Attractive Today?
Here are a few drugmakers we like that are undervalued.
|Editor’s note: Read the latest on how the coronavirus is rattling the markets and what investors can do to navigate it.|
The development of a coronavirus vaccine has brought heightened attention to drug manufacturers, especially the major vaccine producers Pfizer (PFE) /BioNTech (BNTX), Moderna (MRNA), and Johnson & Johnson (JNJ). These names will continue to dominate the news as U.S. herd immunity could be coming by the end of June 2021.
To a lesser extent, drug manufacturers have been on watch since the Democrats took control of the White House and Senate. Director of healthcare equity research Damien Conover, however, doesn’t expect any major changes to U.S. healthcare policy.
“The biopharma lobbying group holds significant power, and the government wants to avoid disrupting innovation for lifesaving research,” says Conover. As a result, drugmakers and managed-care firms still look undervalued.
Stock investors interested in playing the healthcare-news trend may want to watch these U.S.-based drug manufacturers:
We determine the long-term intrinsic value of a stock using the Morningstar Fair Value Estimate. Stocks with price/fair value ratios less than one are undervalued, according to our analysts. Here’s a look at three undervalued names.
Biogen merged with drug manufacturer Idec in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Morningstar’s Karen Andersen, who covers Biogen, reaffirms our $350 per share fair value estimate for the drug manufacturer--as its 2021 first-quarter results were in line with our expectations. Andersen still believes Biogen can fend off competition and earn high returns on invested capital, maintaining its wide Morningstar Economic Moat Rating.
Gilead Sciences (GILD)
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, focused on primarily on HIV and hepatitis B and C. Andersen, who also covers Gilead, maintains our $81 per share fair value estimate. Despite 2021 first-quarter results falling slightly below our expectations, Gilead’s expertise in infectious diseases is “one of the strongest intangible assets supporting the firm's wide moat.”
Merck makes pharmaceutical products to treat several conditions like cardiometabolic disease, cancer, and infections. Conover, who covers the drug manufacturer, reaffirms our $100 per share fair value estimate, despite 2021 first-quarter results falling below our expectations. Conover still believes Merck is undervalued, saying “The investment community [is] underappreciating the firm’s immuno-oncology platform, led by Keytruda as well as a developing pipeline, which reinforces our wide moat rating.”
Sachin Nagarajan does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.